Search
Pomalidomide prolongs survival in refractory myeloma patients
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…
Read moreDaratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read moreIn Memoriam Professor Emeritus Michel Symann
Dear Colleagues,
My dear friend Professor Emeritus Michel Symann passed away on April 23, 2023 at the age of 81.
EHA Congratulates EHA Kick-Off Grant 2022 Winners
The Hague, December 8, 2022 – EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2022 after a rigorous selection process.
Read moreConnecting experts on inherited anemias and iron defects in Budapest
October 12-14, 2023 – Budapest, Hungary
Meeting Chairs:
Ali Taher, American University of Beirut Medical Center, Beirut, Lebanon
Achille Iolascon, University Federico II of Naples, Naples, Italy
In October 2023 EHA and the Specialized Working Group (SWG) on Red Cell and Iron hosted a…
Hematology in the spotlight at EAPM Presidency Conference
April 9, Brussels - The European Alliance for Personalised Medicine is holding its 7th annual presidency conference at the University Foundation in Brussels, and the event will include a session on Hematology - Personalised treatment and personalised prevention.
Read morePress Release: Economic burden of blood disorders in EU is €23 billion
The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
Read moreASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.